QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Science 37 Stock Price, News & Analysis (NASDAQ:SNCE)

$0.25
0.00 (0.00%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.23
$0.26
50-Day Range
$0.24
$0.42
52-Week Range
$0.19
$0.69
Volume
367,158 shs
Average Volume
788,613 shs
Market Capitalization
$29.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Science 37 MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.0% Upside
$1.00 Price Target
Short Interest
Bearish
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.55) to ($0.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

568th out of 952 stocks

Commercial Physical Research Industry

10th out of 12 stocks


SNCE stock logo

About Science 37 Stock (NASDAQ:SNCE)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

SNCE Stock Price History

SNCE Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Science 37 Reports Third Quarter 2023 Financial Results
What Wall Street expects from Science 37's earnings
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Science 37 Holdings Inc.
Science 37 Hldgs Earnings Preview
See More Headlines
Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNCE
Fax
N/A
Employees
460
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.00
High Stock Price Target
$1.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+299.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-50,990,000.00
Net Margins
-206.86%
Pretax Margin
-207.00%

Debt

Sales & Book Value

Annual Sales
$70.15 million
Book Value
$0.83 per share

Miscellaneous

Free Float
111,278,000
Market Cap
$29.86 million
Optionable
Not Optionable
Beta
0.48
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. David Coman (Age 53)
    CEO & Director
    Comp: $796.13k
  • Ms. Christine A. Pellizzari J.D. (Age 55)
    Chief Legal & Human Resources Officer and Secretary
    Comp: $521.58k
  • Ms. Darcy Forman (Age 47)
    Chief Delivery Officer
    Comp: $550.58k
  • Mr. Mike Zaranek (Age 52)
    Chief Financial Officer
  • Irena Lambridis
    VP and Head of Quality Assurance & Compliance
  • Ms. Margie Gimbel Kooman
    Vice President of Marketing & Communications
  • Mr. Drew Bustos
    Chief Strategy & Marketing Officer
  • Mr. Jonathan Cotliar M.D. (Age 51)
    Chief Medical Officer
    Comp: $486.6k
  • Mr. Michael Shipton (Age 51)
    Chief Commercial Officer
  • Mr. Tyler Van Horn
    VP of Corporate Strategy & Chief of Staff














SNCE Stock Analysis - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNCE shares.
View SNCE analyst ratings
or view top-rated stocks.

What is Science 37's stock price target for 2024?

1 brokers have issued 12-month target prices for Science 37's stock. Their SNCE share price targets range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for SNCE
or view top-rated stocks among Wall Street analysts.

How have SNCE shares performed in 2023?

Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE stock has decreased by 39.8% and is now trading at $0.25.
View the best growth stocks for 2023 here
.

Are investors shorting Science 37?

Science 37 saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,630,000 shares, an increase of 50.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 209,600 shares, the days-to-cover ratio is currently 7.8 days. Currently, 2.1% of the shares of the stock are short sold.
View Science 37's Short Interest
.

When is Science 37's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our SNCE earnings forecast
.

How were Science 37's earnings last quarter?

Science 37 Holdings, Inc. (NASDAQ:SNCE) issued its earnings results on Tuesday, November, 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $14.89 million for the quarter, compared to the consensus estimate of $14.70 million. Science 37 had a negative net margin of 206.86% and a negative trailing twelve-month return on equity of 83.09%.

Who are Science 37's major shareholders?

Science 37's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boston Partners (1.19%) and Kent Lake Capital LLC (0.91%).
View institutional ownership trends
.

How do I buy shares of Science 37?

Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNCE) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -